As a former congressman and medical doctor, I would like to alert the public and policymakers to a report that recommends shutting down current regulatory policy – specifically the “Green List” – which grants preferential treatment to some “trusted” foreign firms that import active pharmaceutical ingredients (APIs) into the United States. The report details why that trust-based system is frighteningly obsolete.